Ordering Recommendation

Monitor patient compliance.

Mnemonic
DRUG SCRSP
Methodology

Qualitative Enzyme-Linked Immunosorbent Assay/Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-2 days
Confirmation: 1-4 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Remove plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 3 mL) Also acceptable: Serum.

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles. Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Hemolyzed specimens.

Remarks

Cocaine and cocaethylene are more stable in fluoride-preserved plasma than serum.

Stability

After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years

Reference Interval
Drugs Covered and Cutoff Concentrations
Drugs/Drug Classes
Screen
Amphetamines Effective August 17, 2020
20 ng/mL
Methamphetamine Effective August 17, 2020
20 ng/mL
Barbiturates Effective August 17, 2020
50 ng/mL
Benzodiazepines Effective August 17, 2020
50 ng/mL
Buprenorphine 1 ng/mL
Cannabinoids Effective August 17, 2020
20 ng/mL
Cocaine Effective August 17, 2020
20 ng/mL
Methadone Effective August 17, 2020
25 ng/mL
Opiates Effective August 17, 2020
20 ng/mL
Oxycodone Effective August 17, 2020
20 ng/mL
Phencyclidine Effective August 17, 2020
10 ng/mL

Interpretive Data

Drugs/Drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation. An unconfirmed positive immunoassay screen result may be useful for medical purposes but does not meet forensic standards. The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Compliance Category

Laboratory Developed Test (LDT)

Note

Screen-positive specimens are automatically confirmed by GC/MS and/or LC-MS/MS; additional charges may apply.

Hotline History
N/A
CPT Codes

80307; if reflexed, add 80324; 80345; 80346; 80348; 80349; 80353; 80358; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )

Components
Component Test Code* Component Chart Name LOINC
0092419 Drug Screen Comments, Serum or Plasma 48767-8
0092421 Cannabinoids, S/P, Screen 8172-9
0092422 Cocaine, S/P, Screen 8191-9
0092423 Opiates, S/P, Screen 8219-8
0092424 Phencyclidine, S/P, Screen 8236-2
0092425 Amphetamines, S/P, Screen 8149-7
0092426 Barbiturates, S/P, Screen 20421-4
0092427 Benzodiazepines, S/P, Screen 46976-7
0092428 Methadone, S/P, Screen 59705-4
0092430 Oxycodone, S/P, Screen 13576-4
0093414 Methamphetamine, S/P, Screen 3777-0
2013568 Buprenorphine, S/P, Screen 3413-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Pain Management
Drug Screen 9 Panel, Serum or Plasma - Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation